Natalie McNamee

Natalie McNamee

Private Equity Investor chez Tarnagulla Ventures Pty Ltd.

Consumer Services
Health Technology
Finance

Profil

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Postes actifs de Natalie McNamee

SociétésPosteDébut
Private Equity Investor 01/01/2015
Tous les postes actifs de Natalie McNamee

Anciens postes connus de Natalie McNamee

Formation de Natalie McNamee

University of California San Diego Graduate Degree
University of Melbourne Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Natalie McNamee

Relations

1

Relations au 1er degré

4

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées2

Health Technology

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Natalie McNamee